AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.
Imbruvica was among the first 10 drugs selected for price negotiations under the Inflation Reduction Act of 2022. The law gave the Secretary of Health and Human Services (HHS) authority to negotiate prices for medications sold to Medicare and Medicaid.
